Residual Limb Hyperhidrosis and RimabotulinumtoxinB: A Randomized Placebo-Controlled Study.

Area of Science:

• Medical Research
• Clinical Trials
• Dermatology

Background:

• Hyperhidrosis in residual limbs is a common complication for amputees.
• Excessive sweating can negatively impact prosthetic use and patient comfort.

Purpose of the Study:

• To evaluate the efficacy of rimabotulinumtoxinB (BoNT/B) in treating hyperhidrosis in the residual limbs of individuals with amputation.
• To compare BoNT/B treatment with a placebo for managing residual limb sweating.

Main Methods:

• A randomized, double-blind, placebo-controlled pilot study was conducted.
• Nine male participants with lower limb amputations received either BoNT/B or placebo injections in their residual limbs.
• Sweat production was measured using gravimetric analysis after physical exertion; prosthetic function and pain were secondary outcomes.

Main Results:

• 100% of participants receiving BoNT/B achieved a ≥50% reduction in sweat production, compared to 50% in the placebo group.
• Objective sweat reduction was significantly greater in the BoNT/B group (-72.7%) versus the placebo group (-32.7%).
• No significant changes were observed in phantom limb pain or residual limb pain in either group.

Conclusions:

• RimabotulinumtoxinB (BoNT/B) is an effective treatment for reducing sweat production in individuals with residual limb hyperhidrosis.
• BoNT/B treatment did not demonstrate an effect on pain or perceived prosthetic use.
• Further research may explore optimal dosing and long-term effects of BoNT/B for amputation-related hyperhidrosis.